Deutsche Bank downgraded ImmunoGen (IMGN) to Hold from Buy with a price target of $31, up from $25, after AbbVie (ABBV) announced an acquisition deal at $31 per share, or $10.1B deal value. Given AbbVie’s minimal commercial presence in solid tumors, the firm doesn’t anticipate the FTC to scrutinize the deal and it also does not anticipate any competing offers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN: